Avacta Group (LON:AVCT) Shares Down 4.9% – Here’s What Happened
by Amy Steele · The Cerbat GemAvacta Group Plc (LON:AVCT – Get Free Report)’s stock price fell 4.9% during trading on Monday . The company traded as low as GBX 54 and last traded at GBX 58.50. 2,897,135 shares were traded during mid-day trading, an increase of 93% from the average session volume of 1,497,576 shares. The stock had previously closed at GBX 61.50.
Analysts Set New Price Targets
Separately, Peel Hunt restated a “buy” rating and issued a GBX 99 price target on shares of Avacta Group in a research note on Monday, October 13th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, Avacta Group currently has an average rating of “Buy” and an average price target of GBX 99.
Get Our Latest Research Report on AVCT
Avacta Group Price Performance
The firm has a market cap of £253.69 million, a P/E ratio of -3.33 and a beta of 1.12. The firm’s fifty day simple moving average is GBX 70.43 and its 200 day simple moving average is GBX 58.46. The company has a debt-to-equity ratio of 52.53, a quick ratio of 4.96 and a current ratio of 1.29.
About Avacta Group
Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.
Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).